Semaglutide and Tirzepatide are the two most widely researched GLP-1 compounds available to Canadian researchers. They are closely related but not equivalent, the difference is one additional receptor pathway, and it changes the metabolic profile meaningfully.
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1/GIP agonist: it keeps everything Semaglutide does and adds a second pathway.
| Compound | Receptor Targets | Generation |
|---|---|---|
| Semaglutide | GLP-1 | First, single agonist |
| Tirzepatide | GLP-1 + GIP | Second, dual agonist |
| Retatrutide | GLP-1 + GIP + Glucagon | Third, triple agonist |
The two pathways Tirzepatide engages:
In head-to-head clinical research, Tirzepatide's dual mechanism has produced more pronounced metabolic effects than single-agonist Semaglutide. That said, Semaglutide remains the more extensively studied of the two and the standard comparator for the entire compound class, depth of evidence is its genuine advantage.
One generation further on. Retatrutide is a triple agonist, adding glucagon receptor activation, which increases energy expenditure, on top of the GLP-1 and GIP pathways Tirzepatide covers. See our Retatrutide vs Semaglutide comparison for that pairing.
Vancouver Island Peptides supplies both as domestic research compounds, synthesized at our Vancouver, BC lab partner, HPLC-verified to >99% purity, shipped Canada-wide in discreet packaging. Tirzepatide is available in 10mg and 20mg vials, Semaglutide in 30mg. Nothing crosses a border, so there is no customs seizure risk and no cold-chain uncertainty.
View Tirzepatide Canada View Semaglutide Canada